ReviewFrontiers in cell and developmental biology2026
Context-dependent functions of the aryl hydrocarbon receptor in gastrointestinal cancers: from microenvironmental regulation to precision targeted therapy.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor with context-dependent roles in gastrointestinal (GI) tumor development. Depending on cellular context and microenvironment, AhR can preserve epithelial integrity, suppress inflammation, and inhibit tumor growth, but it can also promote immune evasion and metabolic reprogramming to drive tumor progression. Most existing reviews have focused on a single GI tumor type or functional dimension, and the concept of AhR as a context-dependent signaling hub has not been effectively linked to therapeutic stratification across the full spectrum of GI malignancies. No prior review has systematically compared AhR across five GI cancer types-esophageal, gastric, colorectal, hepatocellular, and pancreatic-or addressed the translational gap between preclinical data and clinical application. This review addresses these gaps in three key ways. First, it provides the first head-to-head comparative analysis of AhR functions across these five cancer types. Second, it adopts a functional stratification framework integrating five core mechanistic dimensions-tumor stemness, epithelial-mesenchymal transition, immune remodeling, metabolic reprogramming, and drug resistance-and proposes a three-dimensional AhR stratification model. Third, it systematically discusses emerging AhR-targeted therapeutic strategies-including antagonists, selective AhR modulators (SAhRMs), PROTACs, combination therapies, and microbiome-based interventions-while critically evaluating translational challenges. By establishing this context-informed framework, we aim to provide a conceptual basis for biomarker-guided evaluation of AhR-targeted strategies in GI cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.